From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener).
Arch Pathol Lab Med. 2019 Feb;143(2):206-211. doi: 10.5858/arpa.2017-0578-OA. Epub 2018 Aug 20.
CONTEXT.—: Paget disease of the breast, in most cases, represents intraepidermal spread of ductal carcinoma in situ. Molecular subtypes of invasive carcinoma of the breast have prognostic and therapeutic significance and show characteristic distribution. Little is known about the distribution of molecular subtypes in Paget disease of the breast.
OBJECTIVES.—: To examine the distribution of molecular subtypes in Paget disease of the breast and to compare them to concurrent invasive carcinoma of the breast, if present.
DESIGN.—: We examined 48 cases of Paget disease of the breast with immunohistochemistry and antibodies against estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as HER2 chromogenic in situ hybridization, to classify the cases into molecular subtypes. Then, we compared the results to the molecular subtypes of associated invasive carcinoma of the breast, if present.
RESULTS.—: The HER2 subtype was the most common found in Paget disease of the breast, followed by the luminal B subtype and 2 cases of the triple-negative subtype. The associated invasive carcinoma cases were most often of the luminal B subtype, followed by the HER2 subtype and the triple-negative subtype. The molecular subtype of Paget disease and invasive carcinoma was congruent in most of the cases.
CONCLUSIONS.—: Molecular subtypes of invasive carcinoma of the breast can already be detected in Paget disease. The distribution of molecular subtypes of Paget disease and of Paget disease-associated invasive carcinoma differs from invasive carcinoma without associated Paget disease, with the HER2 subtype overrepresented in Paget disease and associated invasive carcinoma and the luminal and triple-negative subtypes underrepresented.
在大多数情况下,乳腺 paget 病代表导管原位癌的表皮内扩散。乳腺癌的分子亚型具有预后和治疗意义,并表现出特征性分布。关于乳腺 paget 病中分子亚型的分布知之甚少。
研究乳腺 paget 病中分子亚型的分布,并将其与同时存在的浸润性乳腺癌进行比较。
我们用免疫组织化学和针对雌激素和孕激素受体、人表皮生长因子受体 2(HER2)和 Ki-67 的抗体,以及 HER2 显色原位杂交,对 48 例乳腺 paget 病进行了检测,将病例分为分子亚型。然后,我们将结果与同时存在的浸润性乳腺癌的分子亚型进行比较。
在乳腺 paget 病中最常见的是 HER2 亚型,其次是 luminal B 亚型和 2 例三阴性亚型。同时存在的浸润性乳腺癌病例最常见的是 luminal B 亚型,其次是 HER2 亚型和三阴性亚型。乳腺 paget 病和浸润性乳腺癌的分子亚型在大多数病例中是一致的。
在乳腺 paget 病中已经可以检测到浸润性乳腺癌的分子亚型。乳腺 paget 病和乳腺 paget 病相关浸润性乳腺癌的分子亚型分布与无相关乳腺 paget 病的浸润性乳腺癌不同,HER2 亚型在乳腺 paget 病和相关浸润性乳腺癌中过度表达,而 luminal 和三阴性亚型则表达不足。